FibroGen, Inc. (Nasdaq: FGEN) announced the topline data from the Phase 3 LELANTOS-1 trial, evaluating pamrevlumab as a treatment for non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. 

Unfortunately, the study did not meet its primary endpoint, which was the Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline. 

Following this announcement, $FGEN experienced a decline in pre-market, trading at $16.02, reflecting a decrease of $2.69 or approximately 14.38%.

In contrast, UnitedHealth Group Incorporated (NYSE: UNH) made a positive announcement of a 14% increase in its quarterly cash dividend. The company declared a cash dividend of $1.88 per share, scheduled to be paid on June 27, 2023, to all shareholders of record of UNH common stock as of June 19, 2023. 

$UNH showed a slight increase in pre-market, currently trading at $489.00, up $1.43 or around 0.29%.

Barclays has maintained its Equal-Weight rating on Oracle Corporation (NYSE: ORCL) but raised the price target from $85 to $113. 

In pre-market, $ORCL was trading at $107.30, showing a modest increase of $0.20 (+0.19%).

Similarly, Citigroup has maintained its Buy rating on Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) while raising the price target from $130 to $133. 

$RARE was trading at $52.00 in pre-market, experiencing a slight increase of $0.52 (+1.01%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)